BETY-BIOPSYCHOSOCIAL QUESTIONNAIRE IN PARTİCİPANTS RECEIVING RADIOTHERAPY
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05213416 |
|
Recruitment Status :
Recruiting
First Posted : January 28, 2022
Last Update Posted : January 31, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Questionnaire Radiotherapy |
It is known that psycho-physiological processes affect the results of medical treatment in chronic diseases [1]. In oncological rehabilitation, the psychological, social and functional problems of individuals with cancer are considered together, and goals of the treatment are determined based on this [2]. Biopsychosocial being of human is the main reason for this approach. BETY-Biopsychosocial Questionnaire (BETY-BQ) originates from the Cognitive Exercise Therapy Approach (CETA) which is an innovative exercise approach that targets a holistic treatment techniques in accordance with the biopsychosocial model [3]. This approach contains concepts including function-oriented trunk stabilization exercises, pain management, mood management (dance therapy-authentic movement), sexual knowledge management which are combined with each other. It was first used in patients with ankylosing spondylitis and was observed that besides its positive effects on disease activity, and also provided positive changes in anti-inflammatory parameters [4]. CETA has taken its place in the literature as a biopsychosocial exercise model that can be applied safely in individuals with Multiple Sclerosis [5]. Patients with rheumatism, who have participated in CETA training since 2004, described their recovery characteristics in 2013. The questionary was finalized in 2017 by applying these feedbacks to repetitive statistics and rheumatic patients who did not participate in the group [6]. Validity and reliability studies of the developed scale were conducted in individuals diagnosed with Fibromyalgia, Rheumatoid Arthritis, Osteoarthritis, and individuals with chronic neck and chronic low back pain [3, 7].
Radiotherapy reduces the recurrence rate and provides disease control in patients with cancer [8, 9] However, studies have shown that individuals receiving radiotherapy may experience treatment-related problems such as pain, limitation of movement, and even fractures [10-12]. Cognitive changes such as learning and memory, attention to the painful area, which develop with the influenced limbic system, increase the avoidance of movements. Herewith, the developing muscle spasm, pain and negative mood which results in vicious circle, can be experienced that leads to limitation of movement. Therefore, physical and psychosocial factors are also associated with musculoskeletal disorders [13]. Determining the biopsychosocial status of individuals receiving radiotherapy should be considered when evaluating the effectiveness of treatment. However, when the literature in this field is examined, it is clear that there is a need for biopsychosocial assessment tools.
In the line with this information, the aim of this study is to investigate the validity and reliability of BETY-BQ as a biopsychosocial assessment tool in individuals receiving radiotherapy.
| Study Type : | Observational |
| Estimated Enrollment : | 150 participants |
| Observational Model: | Other |
| Time Perspective: | Cross-Sectional |
| Official Title: | VALIDITY AND RELIABILITY OF THE BETY-BIOPSYCHOSOCIAL QUESTIONNAIRE (BETY-BQ) IN PARTİCİPANTS RECEIVING RADIOTHERAPY |
| Actual Study Start Date : | February 1, 2020 |
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | January 2024 |
- BETY-Biopsychosocial Questionnaire (BETY-BQ [ Time Frame: 1 week ]It is used to evaluate the biopsychosocial process associated with the disease. A 5-point Likert system is used to score this scale. Each question is scored as "0= never, 1=yes rarely, 2=yes sometimes, 3=yes often 4=yes always" and gives a total score over 30 items. A high score means a low biopsychosocial level
- Quality of Life Scale Short Form-36 (SF-36) [ Time Frame: 1 week ]It is one of the frequently used scales to measure quality of life. It evaluates 8 different categories such as general health perception, physical function, social function, pain, mental health, role difficulty due to physical reasons, role difficulty due to emotional reasons, and vitality with a total of 36 sub-items. Items are scored as '0 = worst health condition 100 = best health state'. Each subcategory is scored between 0 and 100 points, with a high score indicating good health.
- Functional Assessment of Cancer Therapy-General (FACT-G) [ Time Frame: 1 week ]It is used to evaluate the multifaceted quality of life in cancer patients; It is a general 27-item scale in which patients evaluate their own condition. There are 4 sub-scales in the questionnaire that evaluate physical, social, emotional and functional status. Participants will be asked how appropriate a particular statement was to them in the past 7 days on a 5-point scale as '0: never; 1: a little, 2: a little; 3: quite; 4: too much'. High scores indicate a high quality of life, and low scores indicate a decreased quality of life
- Hospital Anxiety and Depression Scale (HADS) [ Time Frame: 1 week ]It is a scale consisting of 14 questions which 7 of these questions assess anxiety and 7 assess depression. Likert type measurement is used to evaluate this scale. The cut-off score for the anxiety subscale is 10/11 and for the depression subscale is 7/8. Accordingly, those who score above these scores are considered at risk.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion Criteria:
- Having been diagnosed with cancer
- Receiving radiotherapy from cancer treatments
- Cancer stage between 1-3
- Being between the ages of 18-70
- Having a Mini Mental Test Score of 24 and above
Exclusion Criteria:
- Not being able to read and/or understand the questionaries
- Not being willing to participate in the study
- Having a neurological disease which affects the cognition
- History of orthopaedic surgery in the last three years
- Presence of psychiatric diagnosis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05213416
| Contact: Umut Bahcacı, MSc | +905368607324 | umutbahcaci@gmail.com |
| Turkey | |
| Hacettepe University | Recruiting |
| Ankara, Turkey, 34349 | |
| Contact: Umut Bahcacı +905368607324 umutbahcaci@gmail.com | |
| Contact: Songül Atasavun Uysal, Prof. Dr. | |
| Sub-Investigator: Nilay Şahan | |
| Sub-Investigator: Mustafa Cengiz | |
| Sub-Investigator: Edibe Ünal | |
| Principal Investigator: Songül Atasavun Uysal | |
| Florence Nightingale Hospital | Recruiting |
| Istanbul, Turkey, 34349 | |
| Contact: Umut Bahcacı, MSc 05368607324 umutbahcaci@gmail.com | |
| Sub-Investigator: Şefik İğdem, Prof. Dr. | |
| Principal Investigator: Umut Bahçacı | |
| Study Director: | Songül Atasavun Uysal, Prof. | Hacettepe University |
| Responsible Party: | Umut Bahçacı, Principal investigator, Hacettepe University |
| ClinicalTrials.gov Identifier: | NCT05213416 |
| Other Study ID Numbers: |
BETY-BQ |
| First Posted: | January 28, 2022 Key Record Dates |
| Last Update Posted: | January 31, 2023 |
| Last Verified: | January 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Reliability and Validity Biopsychosocial Models Questionnaire |
Radiotherapy Quality of Life Conservative Treatment |